Does COVID-19 Infection Increase the Risk of Pulmonary Embolism?

NCT ID: NCT04696913

Last Updated: 2021-01-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

347 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-01

Study Completion Date

2021-11-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The World Health Organization (WHO) declared the 2019 novel coronavirus (COVID-19) a pandemic on March 11, 2020. As of 19 July 2020, there have been 14.3 million confirmed cases and over 600,000 confirmed deaths. Up to 14% of infected patients develop interstitial pneumonia, which may evolve to acute respiratory distress syndrome.

COVID-19 associated pulmonary arterial microthrombosis and coagulopathy has prompted physicians to implicate pulmonary embolism (PE) as a potential cause for acute respiratory deterioration.

Literature review reveals few studies of varying size, quality and design. Recent meta-analysis reports venous thromboembolism in approximately 20% of COVID-19 patients. There has yet to be a case-controlled study which proves and quantifies the associated between COVID-19 and PE.Confirming and quantifying this association has numerous clinical implications for the treatment of critically unwell patients with COVID-19 infection. For example, clinicians will be more inclined to investigate and treat sudden deteriorations with the knowledge that pulmonary embolism is the commonest cause for said deteriorations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A retrospective case-control study of all patients who had a CT pulmonary angiogram (CTPA) at NHS Grampian between 3rd March and 20th June 2020 will be conducted.

CTPA reports and test results of Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) for COVID-19 will be reviewed via electronic medical records.

Patients with no COVID-19 RT-PCR test done within 7 days of the CTPA or the same clinical episode will be excluded. Patients who had repeat CTPAs, who are already known to have a PE, and who had CTPAs which are considered to be radiologically inadequate will be excluded.

Patients will be categorised into cases (positive PE) and controls (negative PE).

CTPA images of cases will be reviewed to collect further data about severity, distribution and right heart strain.

Patients' exposure status will also be determined (positive or negative for COVID- 19 infection).

The primary outcome is the number of pulmonary embolism cases related to COVID19.

The secondary outcomes are the severity, distribution of pulmonary embolism as determined by calculated Qanadli score. Presence of right heart strain.

Further data for the multivariate analysis will be obtained from the patient's electronic medical record. Specifically, we will collect data on risk factors for COVID-19 infection and PE to correct for confounding.

Statistical data analysis by various hypothesis tests and multivariate logistic regression will be conducted to determine the odds ratio of developing a PE, given positive COVID-19 infection.

Patients with a positive PE will have their scans reviewed to quantitatively assess their clot burden and degree of right heart strain. The former will be done by calculating a Qanadil score. The latter will be done my measuring the right ventricle- left ventricle ratio. This will allow for a comparison between COVID-19 infected and non-infected patients with PE.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 Pulmonary Embolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pulmonary Embolism Positive

As determined by CT Pulmonary Angiogram

Exposure: Positive COVID-19 infection

Intervention Type DIAGNOSTIC_TEST

Exposure: Positive COVID-19 infection as determined by RT-PCR

Exposure: Negative COVID-19 infection

Intervention Type DIAGNOSTIC_TEST

Exposure: Negative COVID-19 infection as determined by RT-PCR

Pulmonary Embolism Negative

As determined by CT Pulmonary Angiogram

Exposure: Positive COVID-19 infection

Intervention Type DIAGNOSTIC_TEST

Exposure: Positive COVID-19 infection as determined by RT-PCR

Exposure: Negative COVID-19 infection

Intervention Type DIAGNOSTIC_TEST

Exposure: Negative COVID-19 infection as determined by RT-PCR

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exposure: Positive COVID-19 infection

Exposure: Positive COVID-19 infection as determined by RT-PCR

Intervention Type DIAGNOSTIC_TEST

Exposure: Negative COVID-19 infection

Exposure: Negative COVID-19 infection as determined by RT-PCR

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

-Patients who had a CT pulmonary angiogram at NHS Grampian between 3rd March and 20th June 2020.

Exclusion Criteria

* Patients with no COVID-19 RT-PCR test done within 7 days of the CT pulmonary angiogram or the same clinical episode.
* Duplicate CT pulmonary angiograms.
* Patients who are already known to have a pulmonary embolism.
* Patients who had radiologically inadequate CT pulmonary angiograms.
* Patients younger than 16 years old.
* Patients who have incomplete or unavailable notes.
Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Aberdeen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jonathan Wei Sheng PANG, MBChB

Role: CONTACT

+441224552176

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1-073-20

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Surgery in Pulmonary Embolisms
NCT06070129 NOT_YET_RECRUITING
Clinical Pulmonary Embolism
NCT05469724 UNKNOWN